Adma Biologics (ADMA) Gains from Investment Securities (2014 - 2025)

Adma Biologics has reported Gains from Investment Securities for 12 years, with the latest figure at $1.9 million in Q3 2025.

• For the quarter ending Q3 2025, Gains from Investment Securities rose 627.07% year-over-year to $1.9 million; the trailing twelve-month figure through Sep 2025 stood at $1.9 million (up 627.07% YoY), and the FY2024 full-year result was $3.3 million, up 37.11% from the prior year.
• Gains from Investment Securities for Q3 2025 stood at $1.9 million, up from $1.8 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $2.8 million in Q2 2024, with the low at $1000.0 in Q4 2023.
• Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $1.4 million in 2021.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 14182.68% — and 2023, when it slumped 88.53%.
• Adma Biologics' Gains from Investment Securities stood at $8493.0 in 2021, then increased by 2.66% to $8719.0 in 2022, then tumbled by 88.53% to $1000.0 in 2023, then jumped by 25686.7% to $257867.0 in 2024, then surged by 627.07% to $1.9 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.9 million (Q3 2025), $1.8 million (Q2 2025), and $1.7 million (Q1 2025), per Business Quant data.